KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) Operating Expenses (2016 - 2025)

Boston Scientific's Operating Expenses history spans 17 years, with the latest figure at $2.9 billion for Q4 2025.

  • For Q4 2025, Operating Expenses rose 17.93% year-over-year to $2.9 billion; the TTM value through Dec 2025 reached $10.2 billion, up 15.24%, while the annual FY2025 figure was $10.2 billion, 15.24% up from the prior year.
  • Operating Expenses for Q4 2025 was $2.9 billion at Boston Scientific, up from $2.5 billion in the prior quarter.
  • Across five years, Operating Expenses topped out at $2.9 billion in Q4 2025 and bottomed at $1.5 billion in Q1 2021.
  • The 5-year median for Operating Expenses is $2.0 billion (2021), against an average of $2.0 billion.
  • The largest YoY upside for Operating Expenses was 45.75% in 2021 against a maximum downside of 17.54% in 2021.
  • A 5-year view of Operating Expenses shows it stood at $2.0 billion in 2021, then decreased by 7.34% to $1.8 billion in 2022, then increased by 9.02% to $2.0 billion in 2023, then grew by 21.3% to $2.4 billion in 2024, then rose by 17.93% to $2.9 billion in 2025.
  • Per Business Quant, the three most recent readings for BSX's Operating Expenses are $2.9 billion (Q4 2025), $2.5 billion (Q3 2025), and $2.6 billion (Q2 2025).